Molecular Neurodegeneration

Article	Citations
Mitochondria dysfunction in the pathogenesis of Alzheimer’s disease: recent advances	578
Molecular and cellular mechanisms underlying the pathogenesis of Alzheimer’s disease	442
Relationships of gut microbiota, short-chain fatty acids, inflammation, and the gut barrier in Parkinson’s disease	208
The role of TDP-43 mislocalization in amyotrophic lateral sclerosis	191
ApoE in Alzheimer’s disease: pathophysiology and therapeutic strategies	116
Mammalian/mechanistic target of rapamycin (mTOR) complexes in neurodegeneration	114
Neuroimaging advances regarding subjective cognitive decline in preclinical Alzheimer’s disease	109
Neuropathology and molecular diagnosis of Synucleinopathies	108
APOE2: protective mechanism and therapeutic implications for Alzheimer’s disease	105
Tauopathies: new perspectives and challenges	104
TDP-43 Pathology in Alzheimer’s Disease	103
Moving fluid biomarkers for Alzheimer’s disease from research tools to routine clinical diagnostics	100
Proteomic landscape of Alzheimer’s Disease: novel insights into pathogenesis and biomarker discovery	99
Integrated analysis of ultra-deep proteomes in cortex, cerebrospinal fluid and serum reveals a mitochondrial signature in Alzheimer’s disease	98
A blood-based diagnostic test incorporating plasma Aβ42/40 ratio, ApoE proteotype, and age accurately identifies brain amyloid status: findings from a multi cohort validity analysis	98
Plaque associated microglia hyper-secrete extracellular vesicles and accelerate tau propagation in a humanized APP mouse model	97
Microbiota in neuroinflammation and synaptic dysfunction: a focus on Alzheimer’s disease	96
“Don’t Phos Over Tau”: recent developments in clinical biomarkers and therapies targeting tau phosphorylation in Alzheimer’s disease and other tauopathies	95
Cellular and pathological heterogeneity of primary tauopathies	94
Solving neurodegeneration: common mechanisms and strategies for new treatments	93
New approaches to symptomatic treatments for Alzheimer’s disease	92
Comprehensive metabolic profiling of Parkinson’s disease by liquid chromatography-mass spectrometry	91
METTL3-dependent RNA m6A dysregulation contributes to neurodegeneration in Alzheimer’s disease through aberrant cell cycle events	87
Brain mechanisms underlying neuropsychiatric symptoms in Alzheimer’s disease: a systematic review of symptom-general and –specific lesion patterns	82
Post-infection cognitive impairments in a cohort of elderly patients with COVID-19	81

Glycosphingolipids and neuroinflammation in Parkinson’s disease	77
Extracellular protein components of amyloid plaques and their roles in Alzheimer’s disease pathology	76
Oligodendrocyte death and myelin loss in the cuprizone model: an updated overview of the intrinsic and extrinsic causes of cuprizone demyelination	75
APOE in the bullseye of neurodegenerative diseases: impact of the APOE genotype in Alzheimer’s disease pathology and brain diseases	72
Neurofilaments in motor neuron disorders: towards promising diagnostic and prognostic biomarkers	69
Microbial-derived metabolites as a risk factor of age-related cognitive decline and dementia	69
Plaque-associated human microglia accumulate lipid droplets in a chimeric model of Alzheimer’s disease	68
P2RX7 inhibitor suppresses exosome secretion and disease phenotype in P301S tau transgenic mice	68
Protective genes and pathways in Alzheimer’s disease: moving towards precision interventions	64
Constitutively active SARM1 variants that induce neuropathy are enriched in ALS patients	58
Harnessing regulatory T cell neuroprotective activities for treatment of neurodegenerative disorders	58
Microbial involvement in Alzheimer disease development and progression	57
The promise of microRNA-based therapies in Alzheimer’s disease: challenges and perspectives	55
Genome-wide histone acetylation analysis reveals altered transcriptional regulation in the Parkinson’s disease brain	55
Adult-onset CNS myelin sulfatide deficiency is sufficient to cause Alzheimer’s disease-like neuroinflammation and cognitive impairment	54
Impaired NHEJ repair in amyotrophic lateral sclerosis is associated with TDP-43 mutations	52
The gut microbiome in Alzheimer’s disease: what we know and what remains to be explored	51
The role of inflammasomes in vascular cognitive impairment	50
The Alzheimer’s disease-associated protective Plcγ2-P522R variant promotes immune functions	49
Characterization of mitochondrial DNA quantity and quality in the human aged and Alzheimer’s disease brain	48
Clusterin secreted from astrocyte promotes excitatory synaptic transmission and ameliorates Alzheimer’s disease neuropathology	47
The CD33 short isoform is a gain-of-function variant that enhances Aβ1–42 phagocytosis in microglia	47
CNS axonal degeneration and transport deficits at the optic nerve head precede structural and functional loss of retinal ganglion cells in a mouse model of glaucoma	46
The informed road map to prevention of Alzheimer Disease: A call to arms	46
Identification of novel cerebrospinal fluid biomarker candidates for dementia with Lewy bodies: a proteomic approach	45
Selective reduction of astrocyte apoE3 and apoE4 strongly reduces Aβ accumulation and plaque-related pathology in a mouse model of amyloidosis	45
Identification of sixteen novel candidate genes for late onset Parkinson’s disease	44
Utility of plasma Neurofilament light as a diagnostic and prognostic biomarker of the postural instability gait disorder motor subtype in early Parkinson’s disease	44
Behavioral and neural network abnormalities in human APP transgenic mice resemble those of App knock-in mice and are modulated by familial Alzheimer’s disease mutations but not by inhibition of BACE1	43
A novel systems biology approach to evaluate mouse models of late-onset Alzheimer’s disease	43
Guidelines for bioinformatics of single-cell sequencing data analysis in Alzheimer’s disease: review, recommendation, implementation and application	42
Microglial TYROBP/DAP12 in Alzheimer’s disease: Transduction of physiological and pathological signals across TREM2	42
Alzheimer’s disease – the journey of a healthy brain into organ failure	42
Trem2 deficiency differentially affects phenotype and transcriptome of human APOE3 and APOE4 mice	42
Cholesterol alters mitophagy by impairing optineurin recruitment and lysosomal clearance in Alzheimer’s disease	41
FRET-based Tau seeding assay does not represent prion-like templated assembly of Tau filaments	41
Deciphering cellular transcriptional alterations in Alzheimer’s disease brains	40
CX3CR1 deficiency aggravates amyloid driven neuronal pathology and cognitive decline in Alzheimer’s disease	39
The landscape of human tissue and cell type specific expression and co-regulation of senescence genes	39
Trem2 deletion enhances tau dispersion and pathology through microglia exosomes	38
APOΕ4 lowers energy expenditure in females and impairs glucose oxidation by increasing flux through aerobic glycolysis	38
TREM2 in the pathogenesis of AD: a lipid metabolism regulator and potential metabolic therapeutic target	38
Blood-based biomarkers of inflammation in amyotrophic lateral sclerosis	37
Flow-cytometric microglial sorting coupled with quantitative proteomics identifies moesin as a highly-abundant microglial protein with relevance to Alzheimer’s disease	37
Pathological α-synuclein recruits LRRK2 expressing pro-inflammatory monocytes to the brain	37
Modeling the β-secretase cleavage site and humanizing amyloid-beta precursor protein in rat and mouse to study Alzheimer’s disease	36
Sex-dependent calcium hyperactivity due to lysosomal-related dysfunction in astrocytes from APOE4 versus APOE3 gene targeted replacement mice	35
Enhancing GABAergic signaling ameliorates aberrant gamma oscillations of olfactory bulb in AD mouse models	35
Sleep and circadian rhythms in Parkinson’s disease and preclinical models	35
Mitochondrial complex I abnormalities is associated with tau and clinical symptoms in mild Alzheimer’s disease	33

Adiponectin-mimetic novel nonapeptide rescues aberrant neuronal metabolic-associated memory deficits in Alzheimer’s disease	33
Altered network properties in C9ORF72 repeat expansion cortical neurons are due to synaptic dysfunction	32
Human iPSC-derived astrocytes transplanted into the mouse brain undergo morphological changes in response to amyloid-β plaques	32
Higher CSF sTREM2 attenuates ApoE4-related risk for cognitive decline and neurodegeneration	32
BIN1 protein isoforms are differentially expressed in astrocytes, neurons, and microglia: neuronal and astrocyte BIN1 are implicated in tau pathology	31
Tauopathy-associated tau modifications selectively impact neurodegeneration and mitophagy in a novel C. elegans single-copy transgenic model	31
BIN1 is a key regulator of proinflammatory and neurodegeneration-related activation in microglia	30
From basic research to the clinic: innovative therapies for ALS and FTD in the pipeline	30
TREM2 dependent and independent functions of microglia in Alzheimer’s disease	30
Cellular stress signaling and the unfolded protein response in retinal degeneration: mechanisms and therapeutic implications	29
Parkinson mice show functional and molecular changes in the gut long before motoric disease onset	29
Cerebrospinal fluid tau levels are associated with abnormal neuronal plasticity markers in Alzheimer’s disease	29
LRP1 is a neuronal receptor for α-synuclein uptake and spread	29
Novel App knock-in mouse model shows key features of amyloid pathology and reveals profound metabolic dysregulation of microglia	29
Discrimination of MSA-P and MSA-C by RT-QuIC analysis of olfactory mucosa: the first assessment of assay reproducibility between two specialized laboratories	29
Basal lamina changes in neurodegenerative disorders	28
Accumulation of saposin in dystrophic neurites is linked to impaired lysosomal functions in Alzheimer’s disease brains	28
AMPK hyperactivation promotes dendrite retraction, synaptic loss, and neuronal dysfunction in glaucoma	28
Preclinical modeling of chronic inhibition of the Parkinson’s disease associated kinase LRRK2 reveals altered function of the endolysosomal system in vivo	28
TREM2/PLCγ2 signalling in immune cells: function, structural insight, and potential therapeutic modulation	28
Culture shock: microglial heterogeneity, activation, and disrupted single-cell microglial networks in vitro	28
Induction of autophagy mitigates TDP-43 pathology and translational repression of neurofilament mRNAs in mouse models of ALS/FTD	28
Dynamic changes of CSF sPDGFRβ during ageing and AD progression and associations with CSF ATN biomarkers	27
Knock-in models related to Alzheimer’s disease: synaptic transmission, plaques and the role of microglia	27
Impaired antioxidant KEAP1-NRF2 system in amyotrophic lateral sclerosis: NRF2 activation as a potential therapeutic strategy	27
The role of inflammation in neurodegeneration: novel insights into the role of the immune system in C9orf72 HRE-mediated ALS/FTD	26
Circadian clocks, cognition, and Alzheimer’s disease: synaptic mechanisms, signaling effectors, and chronotherapeutics	26
Plasma phospho-tau in Alzheimer’s disease: towards diagnostic and therapeutic trial applications	26
Trem2 Y38C mutation and loss of Trem2 impairs neuronal synapses in adult mice	25
Astrocyte-derived clusterin suppresses amyloid formation in vivo	25
The era of cryptic exons: implications for ALS-FTD	24
Peroxiredoxin 6 mediates protective function of astrocytes in Aβ proteostasis	24
Challenge accepted: uncovering the role of rare genetic variants in Alzheimer’s disease	23
Extrasynaptic NMDA receptors in acute and chronic excitotoxicity: implications for preventive treatments of ischemic stroke and late-onset Alzheimer’s disease	23
Processing of progranulin into granulins involves multiple lysosomal proteases and is affected in frontotemporal lobar degeneration	23
Diabetic phenotype in mouse and humans reduces the number of microglia around β-amyloid plaques	22
Cerebrospinal fluid profile of NPTX2 supports role of Alzheimer’s disease-related inhibitory circuit dysfunction in adults with Down syndrome	22
Beyond association: successes and challenges in linking non-coding genetic variation to functional consequences that modulate Alzheimer’s disease risk	22
Pathophysiology and probable etiology of cerebral small vessel disease in vascular dementia and Alzheimer’s disease	22
Antibody-free measurement of cerebrospinal fluid tau phosphorylation across the Alzheimer’s disease continuum	22
Tau interactome and RNA binding proteins in neurodegenerative diseases	22
The role of ATP-binding cassette subfamily A in the etiology of Alzheimer’s disease	21
The route of SARS-CoV-2 to brain infection: have we been barking up the wrong tree?	21
Anti-amyloid therapies for Alzheimer disease: finally, good news for patients	21
Integrated analysis of the aging brain transcriptome and proteome in tauopathy	20
Pharmacological rescue of cognitive function in a mouse model of chemobrain	20
Amyloid-beta and tau pathologies act synergistically to induce novel disease stage-specific microglia subtypes	20
Conformation-selective tau monoclonal antibodies inhibit tau pathology in primary neurons and a mouse model of Alzheimer’s disease	20
Microglial inclusions and neurofilament light chain release follow neuronal α-synuclein lesions in long-term brain slice cultures	20
Decoding distinctive features of plasma extracellular vesicles in amyotrophic lateral sclerosis	20
FUS-ALS hiPSC-derived astrocytes impair human motor units through both gain-of-toxicity and loss-of-support mechanisms	19
Interleukin-6 deficiency exacerbates Huntington’s disease model phenotypes	19
Calcium-dependent cytosolic phospholipase A2 activation is implicated in neuroinflammation and oxidative stress associated with ApoE4	19
VCP suppresses proteopathic seeding in neurons	19
MicroRNA-100-5p and microRNA-298-5p released from apoptotic cortical neurons are endogenous Toll-like receptor 7/8 ligands that contribute to neurodegeneration	19
Transcriptome deregulation of peripheral monocytes and whole blood in GBA-related Parkinson’s disease	19
Regional binding of tau and amyloid PET tracers in Down syndrome autopsy brain tissue	18
The TGFβ/Notch axis facilitates Müller cell-to-epithelial transition to ultimately form a chronic glial scar	18
Aging-relevant human basal forebrain cholinergic neurons as a cell model for Alzheimer’s disease	18
Divergence, Convergence, and Therapeutic Implications: A Cell Biology Perspective of C9ORF72-ALS/FTD	18
Upregulation of Ca2+-binding proteins contributes to VTA dopamine neuron survival in the early phases of Alzheimer’s disease in Tg2576 mice	18
Opposing effects of apoE2 and apoE4 on microglial activation and lipid metabolism in response to demyelination	18
Nuclear speckle specific hnRNP D-like prevents age- and AD-related cognitive decline by modulating RNA splicing	17
CCR5 antagonist reduces HIV-induced amyloidogenesis, tau pathology, neurodegeneration, and blood-brain barrier alterations in HIV-infected hu-PBL-NSG mice	17
Sex specific molecular networks and key drivers of Alzheimer’s disease	17
17q21.31 sub-haplotypes underlying H1-associated risk for Parkinson’s disease are associated with LRRC37A/2 expression in astrocytes	16
Key role of the CCR2-CCL2 axis in disease modification in a mouse model of tauopathy	16
Activity of Alzheimer’s γ-secretase is linked to changes of interferon-induced transmembrane proteins (IFITM) in innate immunity	16
Increased serum QUIN/KYNA is a reliable biomarker of post-stroke cognitive decline	16
Islet amyloid polypeptide cross-seeds tau and drives the neurofibrillary pathology in Alzheimer’s disease	16
The role of NURR1 in metabolic abnormalities of Parkinson’s disease	16
Axonal energy metabolism, and the effects in aging and neurodegenerative diseases	15
APOE targeting strategy in Alzheimer’s disease: lessons learned from protective variants	15
Mitochondrial dysfunction in Parkinson’s disease – a key disease hallmark with therapeutic potential	15
Neuroprotection by WldS depends on retinal ganglion cell type and age in glaucoma	15
Neuropathology of incidental Lewy body & prodromal Parkinson’s disease	15
Alzheimer risk gene product Pyk2 suppresses tau phosphorylation and phenotypic effects of tauopathy	15
Nuclear import receptors are recruited by FG-nucleoporins to rescue hallmarks of TDP-43 proteinopathy	15
LILRB2-mediated TREM2 signaling inhibition suppresses microglia functions	14
Global neuropathologic severity of Alzheimer’s disease and locus coeruleus vulnerability influences plasma phosphorylated tau levels	14

Prion protein oligomers cause neuronal cytoskeletal damage in rapidly progressive Alzheimer’s disease	14
Dominant mutations in MIEF1 affect mitochondrial dynamics and cause a singular late onset optic neuropathy	13
Small molecule inhibitors of α-synuclein oligomers identified by targeting early dopamine-mediated motor impairment in C. elegans	13
TDP-43-regulated cryptic RNAs accumulate in Alzheimer’s disease brains	13
Quantitative proteomics of cerebrospinal fluid from African Americans and Caucasians reveals shared and divergent changes in Alzheimer’s disease	13
Methods to investigate intrathecal adaptive immunity in neurodegeneration	13
High dose expression of heme oxigenase-1 induces retinal degeneration through ER stress-related DDIT3	13
Aging exacerbates the brain inflammatory micro-environment contributing to α-synuclein pathology and functional deficits in a mouse model of DLB/PD	13
When the infectious environment meets the AD brain	13
SRSF1-dependent inhibition of C9ORF72-repeat RNA nuclear export: genome-wide mechanisms for neuroprotection in amyotrophic lateral sclerosis	13
Common mouse models of tauopathy reflect early but not late human disease	12
Translational molecular imaging and drug development in Parkinson’s disease	12
The role of peripheral inflammatory insults in Alzheimer’s disease: a review and research roadmap	12
RETRACTED ARTICLE: Calcium-dependent cytosolic phospholipase A2 activation is implicated in neuroinflammation and oxidative stress associated with ApoE4	12
Nuclear dynamics and stress responses in Alzheimer’s disease	12
APOE effects on regional tau in preclinical Alzheimer’s disease	12
NF-κB is a critical mediator of post-mitotic senescence in oligodendrocytes and subsequent white matter loss	12
Collusion of α-Synuclein and Aβ aggravating co-morbidities in a novel prion-type mouse model	11
Finding memo: versatile interactions of the VPS10p-Domain receptors in Alzheimer’s disease	11
Cell-autonomous role of Presenilin in age-dependent survival of cortical interneurons	11
Differential regulation of progranulin derived granulin peptides	11
Cerebrospinal fluid lipoproteins inhibit α-synuclein aggregation by interacting with oligomeric species in seed amplification assays	11